Production (Stage)
Brainstorm Cell Therapeutics Inc.
BCLI
$1.24
$0.1412.73%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -26.71% | -34.14% | -13.62% | -9.86% | -2.49% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -34.40% | -45.46% | -38.25% | -27.11% | -23.41% |
| Operating Income | 34.40% | 45.46% | 38.25% | 27.11% | 23.41% |
| Income Before Tax | 28.63% | 32.39% | 14.45% | 42.75% | 35.21% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 28.63% | 32.39% | 14.45% | 42.75% | 35.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 28.63% | 32.39% | 14.45% | 42.75% | 35.21% |
| EBIT | 34.40% | 45.46% | 38.25% | 27.11% | 23.41% |
| EBITDA | 34.70% | 45.91% | 38.65% | 27.38% | 23.62% |
| EPS Basic | 58.32% | 61.53% | 47.23% | 62.45% | 50.78% |
| Normalized Basic EPS | 58.32% | 61.52% | 47.23% | 62.45% | 50.78% |
| EPS Diluted | 58.32% | 61.74% | 47.50% | 62.59% | 50.95% |
| Normalized Diluted EPS | 58.32% | 61.52% | 47.23% | 62.45% | 50.78% |
| Average Basic Shares Outstanding | 65.62% | 74.91% | 69.82% | 54.97% | 36.83% |
| Average Diluted Shares Outstanding | 65.62% | 74.91% | 69.82% | 54.97% | 36.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |